| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
4,660 |
4,457 |
$579K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,540 |
4,311 |
$423K |
| 80053 |
Comprehensive metabolic panel |
2,517 |
2,327 |
$66K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
496 |
471 |
$59K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
161 |
147 |
$37K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
682 |
642 |
$25K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
313 |
288 |
$21K |
| 36415 |
Collection of venous blood by venipuncture |
2,936 |
2,596 |
$12K |
| 0011A |
|
109 |
97 |
$9K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
122 |
110 |
$8K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
71 |
26 |
$8K |
| 0012A |
|
90 |
83 |
$7K |
| 84443 |
Thyroid stimulating hormone (TSH) |
486 |
467 |
$7K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
3,331 |
3,041 |
$7K |
| 86701 |
|
108 |
105 |
$4K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
68 |
65 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
126 |
124 |
$4K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
77 |
72 |
$4K |
| 87070 |
|
80 |
76 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
58 |
57 |
$3K |
| 59025 |
Fetal non-stress test |
16 |
15 |
$3K |
| 86803 |
|
124 |
117 |
$2K |
| 80055 |
|
55 |
54 |
$2K |
| 87653 |
|
18 |
15 |
$1K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
66 |
64 |
$858.60 |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
396 |
367 |
$597.33 |
| 80306 |
|
25 |
24 |
$579.30 |
| 87081 |
|
34 |
30 |
$569.36 |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
13 |
13 |
$297.55 |
| 80061 |
Lipid panel |
13 |
13 |
$252.36 |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
33 |
12 |
$175.47 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
46 |
45 |
$170.16 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
430 |
222 |
$153.72 |
| 71046 |
Radiologic examination, chest; 2 views |
43 |
42 |
$133.69 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
58 |
54 |
$109.96 |
| 82950 |
|
12 |
12 |
$48.20 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
312 |
289 |
$0.00 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
12 |
12 |
$0.00 |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
123 |
116 |
$0.00 |
| 81003 |
|
28 |
27 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
13 |
13 |
$0.00 |
| 81001 |
|
592 |
553 |
$0.00 |
| 71045 |
Radiologic examination, chest; single view |
86 |
78 |
$0.00 |
| 87430 |
|
49 |
46 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
51 |
50 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
40 |
39 |
$0.00 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
14 |
14 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
59 |
52 |
$0.00 |
| 83690 |
|
46 |
43 |
$0.00 |
| G0378 |
Hospital observation service, per hour |
19 |
16 |
$0.00 |